^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
ConfirmMDx

Company:
MDxHealth
Type:
Laboratory Developed Test
Related tests:
Evidence

News

11ms
ADVANCES IN PROSTATE CANCER SCREENING USING BIOMARKERS (ICUC 2023)
PSA is currently the most widely used biomarker as a screening method for prostate cancer. Additional studies of new biomarkers in patients need to be evaluated for better screening and thus clinical management.
ERG (ETS Transcription Factor ERG) • PCA3 (Prostate cancer associated 3)
|
ConfirmMDx • PROGENSA PCA3 Assay • SelectMDx
1year
Biomarkers of Aggressive Prostate Cancer at Diagnosis. (PubMed, Int J Mol Sci)
Another potential direction that has emerged to aid in the CaP diagnosis include multi-parametric magnetic resonance imaging (mpMRI) and bi-parametric magnetic resonance imaging (bpMRI), which in conjunction with clinically validated biomarkers may provide a better approach to predict clinically significant CaP at diagnosis. In this review, we discuss some of the adjunctive biomarker tests along with newer imaging modalities that are currently available to help clinicians decide which patients are at risk of having high-grade CaP on prostate biopsy with the emphasis on clinical utility of the tests across African American (AA) and Caucasian (CA) men.
Journal • Review
|
PCA3 (Prostate cancer associated 3)
|
ConfirmMDx • ExoDx™ Prostate (IntelliScore) Test • SelectMDx
almost2years
Biomarkers for prostate cancer detection and risk stratification. (PubMed, Ther Adv Urol)
Serum, urine, and tissue-based biomarkers are increasingly being incorporated into the clinical care paradigm, but there is still a limited understanding of how to use them most effectively. In the current article, we review test characteristics and clinical performance data for both serum [4 K score, prostate health index (phi)] and urine [SelectMDx, ExoDx Prostate Intelliscore, MyProstateScore (MPS), and PCa antigen 3 (PCA3)] biomarkers to aid decisions regarding initial or repeat biopsies as well as tissue-based biomarkers (Confirm MDx, Decipher, Oncotype Dx, and Polaris) aimed at risk stratifying patients and identifying those patients most likely to benefit from treatment versus surveillance or monotherapy versus multi-modal therapy.
Journal • Review
|
PCA3 (Prostate cancer associated 3)
|
ConfirmMDx • ExoDx™ Prostate (IntelliScore) Test • Oncotype DX Genomic Prostate Score® Assay • SelectMDx
2years
Tissue biomarkers in prostate cancer. (PubMed, Arch Esp Urol)
Since prostate cancer is the mostprevalent neoplasm in men, it is mandatory to stratifypatients correctly to prevent unnecessary biopsiesand overtreatment in low risk patients, as well as designthe best strategy in those with high risk disease.Tissue biomarkers may become a useful tool in precisionmedicine to guide decision making.
Journal
|
ConfirmMDx • ProMark™
2years
Optimal Use of Tumor-Based Molecular Assays for Localized Prostate Cancer. (PubMed, Curr Oncol Rep)
"The current body of literature on this specific topic remains very limited; prospective trials with long-term follow-up are needed to improve our understanding on how these genomic tests fit when combined with our current clinical tools. As the literature matures, it is likely that newer risk calculators that combine our classic clinical variables with genomic and imaging data will be developed to bring about standard protocols for prostate cancer decision-making."
Journal • Review
|
ConfirmMDx • Decipher Prostate Cancer Test • ProMark™ • Prolaris®
over2years
An Update on Biochemical and Genomic Markers for Prostate Cancer. (PubMed, Urol J)
Despite major improvements and innovations in prostate cancer biomarkers, application in current clinical practice is limited. However, these biomarkers have an important role in determining risk, preventing unnecessary prostate biopsies, and predicting prognoses. Additional confirmatory studies will be needed to fully understand the impact of prostate cancer-specific biomarkers.
Journal
|
ConfirmMDx • SelectMDx
over2years
Tumour markers in prostate cancer: The post-prostate-specific antigen era. (PubMed, Ann Clin Biochem)
"In this article, we will review several of those more recent diagnostic markers (4Kscore®, [-2]proPSA and Prostate Health Index, SelectMDx®, ConfirmMDx®, Progensa® Prostate Cancer Antigen 3, Mi-Prostate Score, ExoDx™ Prostate Test, the Stockholm3 test and ERSPC risk calculators) and prognostic markers (OncotypeDX® Genomic Prostate Score, Prolaris®, Decipher® and ProMark®). We will also address some new liquid biopsy approaches - circulating tumour cells and cell-free DNA - with a potential role in metastatic castration-resistant prostate cancer and will briefly give some future perspectives, mostly outlooking epigenetic markers."
Journal
|
PCA3 (Prostate cancer associated 3)
|
ConfirmMDx • Decipher Prostate Cancer Test • ExoDx™ Prostate (IntelliScore) Test • Oncotype DX Genomic Prostate Score® Assay • ProMark™ • Prolaris® • SelectMDx
over2years
Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis. (PubMed, Cancers (Basel))
"Several non-invasive, cost-effective, high-accuracy liquid biopsy diagnostic biomarkers such as Progensa PCA3, MyProstateScore ExoDx, SelectMDx, PHI, 4K, Stockholm3 and ConfirmMDx have been developed in recent years. This article compares current knowledge about them and their potential application in clinical practice."
Journal • Review • Clinical • Liquid biopsy
|
PCA3 (Prostate cancer associated 3)
|
ConfirmMDx • PROGENSA PCA3 Assay • SelectMDx
over3years
Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis. (PubMed, Cancers (Basel))
However, only a small number of recently published head-to-head comparison studies are available. In contrast, recent research has focused on the use of biomarker tests in relation to the (complementary) use of multiparametric magnetic resonance imaging in PCa diagnosis.
Journal • Review
|
PCA3 (Prostate cancer associated 3)
|
ConfirmMDx • Decipher Prostate Cancer Test • Prolaris® • SelectMDx
almost4years
An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer. (PubMed, Expert Rev Mol Diagn)
New biomarkers open the avenue to avoid mpMRI with targeted biopsy in the future, thereby sparing risks and pitfalls associated with this approach. Before this utopia becomes reality, the panel of technologically complementary markers need to prove that they are better, cheaper and faster than current strategies.
Journal
|
ConfirmMDx • ProMark™ • Prolaris® • SelectMDx